Tag: Radiopharmaceuticals
-
Harbour BioMed and Lannacheng Advance Radionuclide Drug Conjugates
Harbour BioMed and Lannacheng Forge a Long-Term Strategic Collaboration Harbour BioMed has entered into a long-term strategic collaboration with Lannacheng to accelerate the discovery and development of next-generation radionuclide drug conjugates (RDCs). The partnership, announced by Harbour BioMed and Lannacheng, signals a shared commitment to advancing radiopharmaceuticals that combine targeted antibodies with radionuclide therapy to…
-
Radionuclide Drug Conjugates: Harbour BioMed & Lannacheng Alliance
Harbour BioMed and Lannacheng Forge a Long-Term Strategic Collaboration In a bold move to accelerate precision oncology, Harbour BioMed and Lannacheng have announced a long-term strategic collaboration focused on the development of next-generation radionuclide drug conjugates (RDCs). The partnership appears to align with a broader industry trend toward targeted radiopharmaceuticals that combine the specificity of…
-
Fast SPECT Acquisitions Enable STP Dosimetry for 177Lu-PSMA in mCRPC
Overview Single time-point (STP) dosimetry is gaining traction in the management of metastatic castration-resistant prostate cancer (mCRPC) treated with Lutetium-177 labeled PSMA (177Lu-PSMA). This approach aims to estimate absorbed radiation doses with a single post-therapy imaging session, typically around 48 hours, reducing imaging burden and resource use compared with traditional multi-time-point (MTP) dosimetry. Here we…
-
Lu-177 PNT2002 Combined with SBRT Delays Prostate Cancer Progression
Overview New data presented at the American Society for Radiation Oncology (ASTRO) meeting suggest that adding the radiopharmaceutical Lu-177 PNT2002 to stereotactic body radiation therapy (SBRT) can significantly delay disease progression in men with oligometastatic, or limited, prostate cancer. The LUNAR trial compared SBRT alone to a two-cycle course of Lu-177 PNT2002 followed by SBRT,…
-
Radiopharmaceutical Therapy Boosts Radiation to Slow Prostate Cancer
New Findings from the LUNAR Trial A landmark phase II study, known as the LUNAR trial, reports that people with recurrent prostate cancer and a limited number of metastases lived significantly longer without disease progression when a radiopharmaceutical drug was given before targeted radiation therapy, compared with high-precision radiation alone. The randomized study evaluated whether…